Regulatory role of CD39 and CD73 in tumor immunity

被引：6
|
作者：
Kaplinsky, Nicole [1 ]
Williams, Kada [1 ]
Watkins, Dean [1 ]
Adams, Molly [1 ]
Stanbery, Laura [2 ]
Nemunaitis, John [2 ]
机构：
[1] Univ Toledo, Coll Med, Toledo, OH 43614 USA
[2] Gradalis Inc, Dallas, TX 75006 USA
来源：
FUTURE ONCOLOGY | 2024年 / 20卷 / 19期
关键词：
adenosine pathway; antigen; CD39; CD73; ENTPD1; immunotherapy; tumor microenvironment; T-CELLS; EXTRACELLULAR ADENOSINE; ATP; DISEASE; GROWTH; CANCER; INHIBITION; THERAPY;
D O I：
10.2217/fon-2023-0871
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CD39 is the rate-limiting enzyme for the molecular signal cascade leading to the generation of ADP and adenosine monophosphate (AMP). In conjunction with CD73, CD39 converts adenosine triphosphate (ATP) to ADP and AMP, which leads to the accumulation of immunosuppressive adenosine in the tumor microenvironment. This review focuses on the role of CD39 and CD73 in immune response and malignant progression, including the expression of CD39 within the tumor microenvironment and its relationship to immune effector cells, and its role in antigen presentation. The role of CD39- and CD73-targeting therapeutics and cancer-directed clinical trials investigating CD39 modulation are also explored.
引用
收藏
页码：1367 / 1380
页数：14
相关论文
共 50 条
  • [1] CD39 and CD73 in immunity and inflammation
    Antonioli, Luca
    Pacher, Pal
    Vizi, E. Sylvester
    Hasko, Gyoergy
    TRENDS IN MOLECULAR MEDICINE, 2013, 19 (06) : 355 - 367
  • [2] The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
    Jiang, Xuan
    Wu, Xiaofang
    Xiao, Yuxi
    Wang, Penglin
    Zheng, Jiamian
    Wu, Xiuli
    Jin, Zhenyi
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [3] The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
    Allard, Bertrand
    Longhi, Maria Serena
    Robson, Simon C.
    Stagg, John
    IMMUNOLOGICAL REVIEWS, 2017, 276 (01) : 121 - 144
  • [4] Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints
    Baghbani, Elham
    Noorolyai, Saeed
    Shanehbandi, Dariush
    Mokhtarzadeh, Ahad
    Aghebati-Maleki, Leili
    Shahgoli, Vahid Khaze
    Brunetti, Oronzo
    Rahmani, Shima
    Shadbad, Mahdi Abdoli
    Baghbanzadeh, Amir
    Silvestris, Nicola
    Baradaran, Behzad
    LIFE SCIENCES, 2021, 282
  • [5] Antagonists of CD39 and CD73 potentiate doxycycline repositioning to induce a potent antitumor immune response
    Dalai, Parameswar
    Shah, Dhruvi
    Shah, Jigna
    Soni, Kinal
    Mohanty, Aditya
    Thanki, Kavya
    Dave, Heena
    Agrawal-Rajput, Reena
    CELLULAR SIGNALLING, 2025, 125
  • [6] The role of ectonucleotidases CD39 and CD73 and adenosine signaling in solid organ transplantation
    Roberts, Veena
    Stagg, John
    Dwyer, Karen M.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [7] Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39
    Goueli, Said A.
    Hsiao, Kevin
    PLOS ONE, 2019, 14 (10):
  • [8] Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas
    Xu, Shuo
    Shao, Qian-Qian
    Sun, Jin-Tang
    Yang, Ning
    Xie, Qi
    Wang, Dong-Hai
    Huang, Qi-Bing
    Huang, Bin
    Wang, Xin-Yu
    Li, Xin-Gang
    Qu, Xun
    NEURO-ONCOLOGY, 2013, 15 (09) : 1160 - 1172
  • [9] Low expression of CD39 and CD73 genes in centenarians compared with octogenarians
    Crooke, Almudena
    Martinez-Henandez, Juan
    Martinez-Lopez, Joaquin
    Cruz-Jentoft, Alfonso
    Huete-Toral, Fernando
    Pintor, Jesus
    IMMUNITY & AGEING, 2017, 14
  • [10] CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma
    Wang, Lin-Lin
    Tang, Hua-Ping
    Shi, Guo-Chao
    Wan, Huan-Ying
    Tang, Wei
    Hou, Xiao-Xia
    Pan, Li-Na
    Shi, Bao-Yu
    Tao, Lian-Qin
    MOLECULAR MEDICINE REPORTS, 2013, 8 (05) : 1432 - 1438
12345